Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | $89.00 | Neutral → Buy | CL King |
| 3/11/2022 | $9.00 → $8.00 | Outperform | RBC Capital |
| 12/20/2021 | $8.50 → $9.00 | Outperform | RBC Capital |
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced the appointment of Luis E. Rojo as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. After a 31-year Stepan career, Scott R. Behrens is departing the Company to pursue other opportunities. "We thank Scott for his leadership and his many contributions to the growth and diversification of Stepan over his career with the Company. During his various roles in R&D, sales and marketing, and leadership, he helped diversify our market presence,
NORTHBROOK, Ill., Feb. 15, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) announced today the appointment of Susan M. Lewis as a Director of Stepan, effective on February 15, 2024. Ms. Lewis spent over 30 years at Dow Inc., a materials science company, and was part of the management team of Corteva, Inc., a global agriculture company, following its spinoff from DowDuPont Inc. Ms. Lewis served as Senior Vice President, Global Operations of Corteva from 2018 until her retirement in 2021, after which she worked as a business and executive consultant through 2023. Ms. Lewis held senior management roles with operations, sustainability and risk management responsibilities and led organizational r
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has approved an increase of $0.01 per share, or 2.7%, on the quarterly cash dividend on the Company's common stock. The dividend of $0.385 per share is payable on December 13, 2024, to common stockholders of record on November 29, 2024. The increase marks the 57th consecutive year in which the quarterly dividend on the Company's common stock has increased. Corporate Profile Stepan Company is a major manufacturer of specialty and intermediate chemic
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: Third Quarter 2024 Highlights Reported net income was $23.6 million, up 88% versus prior year. Adjusted net income(1) was $23.7 million, up 61% versus prior year, largely due to higher margins and a lower effective tax rate. The year-over-year change in effective tax rate positively impacted net income by $6.8 million, or $0.30 per diluted share.EBITDA(2) was $53.0 million and Adjusted EBITDA(2) was $53.1 million, up 18% and 11% respectively, year-over-year.Global sales volume was down 1%
NORTHBROOK, Ill., Oct. 9, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its third quarter 2024 earnings results on Wednesday, October 30, 2024 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 9:00 a.m. ET (8:00 a.m. CT). The call will be hosted by Scott R. Behrens, President and Chief Executive Officer, and Luis E.
4 - STEPAN CO (0000094049) (Issuer)
SC 13G - STEPAN CO (0000094049) (Subject)
SC 13G/A - STEPAN CO (0000094049) (Subject)
SC 13G/A - STEPAN CO (0000094049) (Subject)
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has approved an increase of $0.01 per share, or 2.7%, on the quarterly cash dividend on the Company's common stock. The dividend of $0.385 per share is payable on December 13, 2024, to common stockholders of record on November 29, 2024. The increase marks the 57th consecutive year in which the quarterly dividend on the Company's common stock has increased. Corporate Profile Stepan Company is a major manufacturer of specialty and intermediate chemic
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: Third Quarter 2024 Highlights Reported net income was $23.6 million, up 88% versus prior year. Adjusted net income(1) was $23.7 million, up 61% versus prior year, largely due to higher margins and a lower effective tax rate. The year-over-year change in effective tax rate positively impacted net income by $6.8 million, or $0.30 per diluted share.EBITDA(2) was $53.0 million and Adjusted EBITDA(2) was $53.1 million, up 18% and 11% respectively, year-over-year.Global sales volume was down 1%
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced the appointment of Luis E. Rojo as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. After a 31-year Stepan career, Scott R. Behrens is departing the Company to pursue other opportunities. "We thank Scott for his leadership and his many contributions to the growth and diversification of Stepan over his career with the Company. During his various roles in R&D, sales and marketing, and leadership, he helped diversify our market presence,
10-Q - STEPAN CO (0000094049) (Filer)
8-K - STEPAN CO (0000094049) (Filer)
8-K - STEPAN CO (0000094049) (Filer)
"Looking forward, we believe sales volumes will continue to gradually improve due to ongoing recovery in Rigid Polyols and growth in Surfactant volumes including the expected recovery of the Agricultural business in the second half of the year," said Scott Behrens, President and Chief Executive Officer.
Stepan (NYSE:SCL) reported quarterly Adj earnings of $0.64 per share which beat the analyst consensus estimate of $0.35 by 82.86 percent. This is a 9.86 percent decrease over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $551.418 million which missed the analyst consensus estimate of $575.825 million by 4.24 percent. This is a 15.35 percent decrease over sales of $651.436 million the same period last year.
CL King upgraded Stepan Company from Neutral to Buy and set a new price target of $89.00
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $8.00 from $9.00 previously
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $9.00 from $8.50 previously